Paraproteinemic neuropathy

키워드

참고문헌 (99)

1. Saleun JP, "Monoclonal gammopathies in the adult population of Finistère, France", J Clin Pathol, 35, pp.63~68 (1982)
2. Kelly JJ Jr, "Prevalence of monoclonal protein in peripheral neuropathy", Neurology, 31, pp.1480~1483 (1981)
3. Ramchandren S, "An update on monoclonal gammopathy and neuropathy", Curr Neurol Neurosci Rep, 12, pp.102~110 (2012)
4. Kelly JJ Jr, "Peripheral neuropathies associated with monoclonal proteins: a clinical review", Muscle Nerve, 8, pp.138~150 (1985)
5. Joint Task Force of the EFNS and the PNS, "European Federation of Neurological Societies", Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision, 2010, pp.15, 185~195
6. England JD, "Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Elec trodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation", PM R, 1, pp.5~13 (2009)
7. Kyle RA, "Polyneuropathies associated with plasma cell dyscrasias. Topics in the Neurosciences, Vol 5", pp.91~103 (1987), Springer
8. Raheja D, "Paraproteinemic neuropathies", Muscle Nerve, 51, pp.1~13 (2015)
9. Berenson JR, "Monoclonal gammopathy of undetermined significance: a consensus statement", Br J Haematol, 150, pp.28~38 (2010)
10. Kyle RA, "Monoclonal gammopathy of undetermined significance and solitary plasmacytoma. Implications for progression to overt multiple myeloma", Hematol Oncol Clin North Am, 11, pp.71~87 (1997)
11. Landgren O, "Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology", Hematology Am Soc Hematol Educ Program, 2010, pp.295~302 (2010)
12. Rajkumar SV, "Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance", Blood, 106, pp.812~817 (2005)
13. van de Poel MH, "Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital in southeastern Netherlands", Br J Haematol, 91, pp.121~125 (1995)
14. Vuckovic J, "Prognosis in monoclonal gammopathy of undetermined significance", Br J Haematol, 97, pp.649~651 (1997)
15. Gosselin S, "Neuropathy associated with monoclonal gammopathies of undetermined significance", Ann Neurol, 30, pp.54~61 (1991)
16. Katz JS, "Distal acquired demyelinating symmetric neuropathy", Neurology, 54, pp.615~620 (2000)
17. Nobile-Orazio E, "Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy", Ann Neurol, 36, pp.416~424 (1994)
18. Gorson KC, "Clinical features, evaluation, and treatment of patients with polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS)", J Clin Apher, 14, pp.149~153 (1999)
19. Silberman J, "Review of peripheral neuropathy in plasma cell disorders", Hematol Oncol, 26, pp.55~65 (2008)
20. Benedetti L, "Long-term effect of rituximab in anti-mag polyneuropathy", Neurology, 71, pp.1742~1744 (2008)
21. Yeung KB, "The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings", J Neurol, 238, pp.383~391 (1991)
22. Rajabally YA, "Neuropathy and paraproteins : review of a complex association", Eur J Neurol, 18, pp.1291~1298 (2011)
23. Nobile-Orazio E, "Longterm prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies", Brain, 123(Pt 4), pp.710~717 (2000)
24. Chassande B, "Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical", electrophysiological features in 40cases, 1998, pp.21, 55~62
25. Franssen H, "Pathophysiology of immune-mediated demyelinating neuropathies--part II : neurology", Muscle Nerve, 49, pp.4~20 (2014)
26. Attarian S, "Terminal latency index and modified F ratio in distinction of chronic demyelinating neuropathies", Clin Neurophysiol, 112, pp.457~463 (2001)
27. Steck AJ, "Anti-myelin-associated glycoprotein neuropathy", Curr Opin Neurol, 19, pp.458~463 (2006)
28. Lombardi R, "IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy", Ann Neurol, 57, pp.180~187 (2005)
29. Lunn MP, "Anti-myelin-associated glycoprotein antibodies alter neurofilament spacing", Brain, 125(Pt 4), pp.904~911 (2002)
30. Dalakas MC, "A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy", Ann Neurol, 40, pp.792~795 (1996)
31. Comi G, "A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy", J Neurol, 249, pp.1370~1377 (2002)
32. Lunn MP, "Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropa thies", Cochrane Database Syst Rev, 16, pp.CD002827~ (2012)
33. Mariette X, "A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group", J Neurol Neurosurg Psychiatry, 63, pp.28~34 (1997)
34. Mariette X, "A randomised double blind trial versus placebo does not confirm the benefit of alpha-interferon in polyneuropathy associated with monoclonal IgM", J Neurol Neurosurg Psychiatry, 69, pp.279~280 (2000)
35. Oksenhendler E, "Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group", J Neurol Neurosurg Psychiatry, 59, pp.243~247 (1995)
36. Niermeijer JM, "Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy", Neurology, 69, pp.50~59 (2007)
37. Dalakas MC, "Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy", Ann Neurol, 65, pp.286~293 (2009)
38. Iancu Ferfoglia R, "Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study", J Peripher Nerv Syst, 21, pp.10~14 (2016)
39. Pestronk A, "Treatment of IgM antibody associated polyneuropathies using rituximab", J Neurol Neurosurg Psychiatry, 74, pp.485~489 (2003)
40. Niermeijer JM, "Rituximab for polyneuropathy with IgM monoclonal gammopathy", J Neurol Neurosurg Psychiatry, 80, pp.1036~1039 (2009)
41. Magy L, "Polyneuropathy associated with IgG", IgA monoclonal gammopathy:a clinical and electrophysiological study of 15 cases, 2003, pp.10, 677~685
42. Gorson KC, "Axonal neuropathy associated with monoclonal gammopathy of undetermined significance", J Neurol Neurosurg Psychiatry, 63, pp.163~168 (1997)
43. Di Troia A, "Clinical features and anti-neural reactivity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance", J Neurol Sci, 164, pp.64~71 (1999)
44. Hermosilla E, "Peripheral neuropathy associated with monoclonal IgG of undetermined significance: clinical, electrophysiologic, pathologic and therapeutic study of 14 cases", J Peripher Nerv Syst, 1, pp.139~148 (1996)
45. Nobile-Orazio E, "Neuropathy and monoclonal gammopathy", Curr Opin Neurol, 14, pp.615~620 (2001)
46. Vallat JM, "Link between peripheral neuropathy and monoclonal dysglobulinemia: a study of 66 cases", J Neurol Sci, 137, pp.124~130 (1996)
47. Wicklund MP, "Paraproteinemic neuropathy", Curr Treat Options Neurol, 3, pp.147~156 (2001)
48. Saperstein DS, "Clinical spectrum of chronic acquired demyelinating polyneuropathies", Muscle Nerve, 24, pp.311~324 (2001)
49. Dyck PJ, "Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance", N Engl J Med, 325, pp.1482~1486 (1991)
50. Stork AC, "Treatment for IgG and IgA paraproteinaemic neuropathy", Cochrane Database Syst Rev, (3), pp.CD005376~ (2015)
51. Mauermann ML, "Paraproteinemic neuropathies", Continuum (Minneap Minn), 20, pp.1307~1322 (2014)
52. Sobol U, "Neurologic aspects of plasma cell disorders", Handb Clin Neurol, 120, pp.1083~1099 (2014)
53. Chaudhry V, "Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy", J Peripher Nerv Syst, 13, pp.275~282 (2008)
54. Richardson PG, "Management of treatment-emergent peripheral neuropathy in multiple myeloma", Leukemia, 26, pp.595~608 (2012)
55. Walsh JC, "The neuropathy of multiple myeloma. An electrophysiological and histological study", Arch Neurol, 25, pp.404~414 (1971)
56. Kelly JJ Jr, "The electrodiagnostic findings in peripheral neuropathy associated with monoclonal gammopathy", Muscle Nerve, 6, pp.504~509 (1983)
57. Ohi T, "Axonal attenuation and secondary segmental demyelination in myeloma neuropathies", Ann Neurol, 17, pp.255~261 (1985)
58. Richardson PG, "Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy", J Clin Oncol, 27, pp.3518~3525 (2009)
59. Briani C, "Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma:results from a single-centre prospective study", J Peripher Nerv Syst, 18, pp.19~24 (2013)
60. Dispenzieri A., "POEMS syndrome: update on diagnosis, risk-stratification, and management", Am J Hematol, 90, pp.951~962 (2015)
61. Dispenzieri A., "POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management", Am J Hematol, 86, pp.591~601 (2011)
62. Dispenzieri A, "POEMS syndrome: definitions and long-term outcome", Blood, 101, pp.2496~2506 (2003)
63. Nasu S, "Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy", J Neurol Neurosurg Psychiatry, 83, pp.476~479 (2012)
64. Sung JY, "Patterns of nerve conduction abnormalities in POEMS syndrome", Muscle Nerve, 26, pp.189~193 (2002)
65. Mauermann ML, "Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP", J Neurol Neurosurg Psychiatry, 83, pp.480~486 (2012)
66. Guo X, "Electrophysiological features of POEMS syndrome and chronic inflammatory demyelinating polyneuropathy", J Clin Neurosci, 21, pp.587~590 (2014)
67. Scarlato M, "Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis", Brain, 128(Pt 8), pp.1911~1920 (2005)
68. Arimura K., "Increased vascular endothelial growth factor(VEGF)is causative in crow-fukase syndrome", Rinsho Shinkeigaku, 39, pp.84~85 (1999)
69. Kuwabara S, "Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome", Cochrane Database Syst Rev, (6), pp.CD006828~ (2012)
70. Suh YG, "The role of radiotherapy in the management of POEMS syndrome", Radiat Oncol, 9, pp.265~ (2014)
71. Humeniuk MS, "Outcomes of patients with POEMS syndrome treated initially with radiation", Blood, 122, pp.68~73 (2013)
72. Li J, "Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome", Blood, 117, pp.6445~6449 (2011)
73. Dispenzieri A, "Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome", Eur J Haematol, 80, pp.397~406 (2008)
74. Imai N, "Relapse of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome without increased level of vascular endothelial growth factor following successful autologous peripheral blood stem cell transplantation", Neuromuscul Disord, 19, pp.363~365 (2009)
75. Chu BF, "Long-term therapy with lenalidomide in a patient with POEMS syndrome", Eur J Case Rep Intern Med, 1 (2014)
76. Dispenzieri A, "Lenalidomide therapy in a patient with POEMS syndrome", Blood, 110, pp.1075~1076 (2007)
77. Kuwabara S, "Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome", J Neurol Neurosurg Psychiatry, 79, pp.1255~1257 (2008)
78. Ohguchi H, "Successful treatment with bortezomib and thalidomide for POEMS syndrome", Ann Hematol, 90, pp.1113~1114 (2011)
79. Kanai K, "Failure of treatment with anti-VEGF monoclonal antibody for long-standing POEMS syndrome", Intern Med, 46, pp.311~313 (2007)
80. Ohwada C, "Successful combination treatment with bevacizumab, thalidomide and autologous PBSC for severe POEMS syndrome", Bone Marrow Transplant, 43, pp.739~740 (2009)
81. Gertz MA, "Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management", Am J Hematol, 88, pp.703~711 (2013)
82. Klein CJ, "The neuropathies of waldenström’s macroglobulinemia (WM) and IgM-MGUS", Can J Neurol Sci, 38, pp.289~295 (2011)
83. Ansell SM, "Diagnosis and management of Waldenström macroglobulinemia:mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines", Mayo Clin Proc, 85, pp.824~833 (2010)
84. Buske C, "The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma:results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)", Leukemia, 23, pp.153~161 (2009)
85. Lee HS, "Clinical factors associated with response or survival after chemotherapy in patients with waldenström macroglobulinemia in Korea.", Biomed Res Int, 2014, pp.253243~ (2014)
86. Owen RG, "Guidelines on the diagnosis and management of waldenström macroglobulinaemia", Br J Haematol, 165, pp.316~333 (2014)
87. Usmani S, "Autologous stem cell transplantation as a care option in waldenström’s macroglobulinemia", Clin Lymphoma Myeloma Leuk, 11, pp.139~142 (2011)
88. Bachanova V, "Hematopoietic cell transplantation for waldenström macroglobulinemia", Bone Marrow Transplant, 47, pp.330~336 (2012)
89. Gertz MA, "Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment", Am J Hematol, 88, pp.416~425 (2013)
90. Rajkumar SV, "Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy", Am J Med, 104, pp.232~237 (1998)
91. Kelly JJ, "Neurologic complications of primary systemic amyloidosis", Rev Neurol Dis, 3, pp.173~181 (2006)
92. Kyle RA, "Primary systemic amyloidosis : clinical and laboratory features in 474 cases", Semin Hematol, 32, pp.45~59 (1995)
93. Benson MD, "The molecular biology and clinical features of amyloid neuropathy", Muscle Nerve, 36, pp.411~423 (2007)
94. Sanchorawala V, "Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation", Blood, 110, pp.3561~3563 (2007)
95. Cordes S, "Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis", Cancer, 118, pp.6105~6109 (2012)
96. Palladini G, "Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis", Blood, 110, pp.787~788 (2007)
97. Moreau P, "Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1", 2 dose-escalation study, 2010, pp.116, 4777~4782
98. Sitia R, "Bortezomib in the treatment of AL amyloidosis: targeted therapy?", Haematologica, 92, pp.1302~1307 (2007)
99. Rison RA, "Paraproteinemic neuropathy: a practical review", BMC Neurol, 16, pp.13~ (2016)

관련 논문AI추천